{"paper_id": "1ea63639e404e247978da31984bfec88dcce1bc9", "metadata": {"title": "Drug treatment of coronavirus disease 2019 (COVID-19) in China", "authors": [{"first": "Z", "middle": [], "last": "Liu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "J.-Y", "middle": [], "last": "Feng", "suffix": "", "affiliation": {}, "email": ""}, {"first": "R", "middle": [], "last": "Ji", "suffix": "", "affiliation": {}, "email": ""}, {"first": "L", "middle": [], "last": "Jin", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Z.-L", "middle": [], "last": "Li", "suffix": "", "affiliation": {}, "email": ""}, {"first": "H.-B", "middle": [], "last": "", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [{"text": "1", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "ribavirin should be used in combination with alpha-interferon or lopinavir/ritonavir, 500 mg 1 per adult, 2 to 3 times per day, and be given by intravenous infusion, and the course of 2 treatment should not exceed ten days (Zehua Zhang et al., 2020). 3", "cite_spans": [], "ref_spans": [], "section": ""}, {"text": "Glucocorticoids are not only the most important hormones regulating stress response, but 5 also the most widely used and effective anti-inflammatory and immunosuppressant agent in 6 clinic (Allan et al., 1984) . Glucocorticoids are fat-soluble hormones that pass through the 7 cell membrane and bind to glucocorticoid receptor (GR). GR is a macromolecular complex 8 of 90 kDa, which is composed of heat shock protein (hsp90) and p59 protein. Hsp90 9 dissociates from the complex, and the activated GCS-GR complex rapidly enters the 10 nucleus, binds to the glucocorticoid response components on the target gene promoter in the 11 form of a dimer, and thus to promotes or inhibits the transcription of the target gene, and 12 finally produces pharmacological effects or side effects by regulating the gene products 13 (Wilckens and Rijk, 1997) . In addition, GCS-GR complex interacts with other transcription 14 factors such as NF-\u03baB to inhibit the expression of inflammatory genes and directly 15 influence the gene regulation and anti-inflammation (Rhen and Cidlowski, 2005; Sch\u00e4cke et 16 al., 2002) . In emergency or critical cases, glucocorticoid is often the first choice for the 17 treatment for primary or secondary (pituitary) adrenocortical dysfunction, mainly combined 18 with physiological dose of hydrocortisone or cortisone as a supplementary or replacement 19 therapy. 20", "cite_spans": [{"start": 189, "end": 209, "text": "(Allan et al., 1984)", "ref_id": "BIBREF5"}, {"start": 442, "end": 449, "text": "Hsp90 9", "ref_id": null}, {"start": 817, "end": 842, "text": "(Wilckens and Rijk, 1997)", "ref_id": "BIBREF119"}, {"start": 1049, "end": 1075, "text": "(Rhen and Cidlowski, 2005;", "ref_id": "BIBREF89"}, {"start": 1076, "end": 1100, "text": "Sch\u00e4cke et 16 al., 2002)", "ref_id": null}], "ref_spans": [], "section": "Glucocorticoids (GCs) 4"}, {"text": "The common clinical glucocorticoids are prednisone, methylprednisone, betamethasone, 21 11 beclomethasone propionate, prednisone, prednisolone, hydrocortisone and dexamethasone 1 etc. Glucocorticoids had been used to treat SARS and MERS, resulting in lower mortality 2 and shorter hospitalization stay, and were not associated with significant secondary lower 3 respiratory infection and other complications. However, more evidence is needed either for 4 supporting or opposing the systemic therapeutic administration of glucocorticoids in 5 patients with SARS-CoV-2 infection (Qin et al., 2020 a variety of immune cells  20  and improves the immunity, while IFN-\u03b2 takes effect by inhibiting the adsorption of certain  1   viruses, enhancing phagocytosis of natural killer cells and mononuclear macrophages Tocilizumab is a recombinant humanized anti-IL-6 receptor (IL-6R) monoclonal antibody, 21 13 which can specifically bind to soluble and membrane-bound IL-6 receptors and inhibit 1 signal transduction mediated by IL-6, thereby reducing inflammation and blocking cytokine 2 storm caused by COVID-19 (Scheinecker et al., 2009) . Tocilizumab was initially used in a 3 study of 21 Chinese patients with severe COVID-19 (Xu et al., 2020a) . Based on its 4 encouraging therapeutic effect, a multi-center, large-scale clinical trial 5 (ChiCTR2000029765) was further initiated, and approximately 500 severe or critically ill 6 patients were included. In the DTPNCP (Trial Version 7), tocilizumab was recommended 7", "cite_spans": [{"start": 88, "end": 90, "text": "11", "ref_id": null}, {"start": 577, "end": 594, "text": "(Qin et al., 2020", "ref_id": "BIBREF88"}, {"start": 897, "end": 899, "text": "13", "ref_id": null}, {"start": 1104, "end": 1130, "text": "(Scheinecker et al., 2009)", "ref_id": null}, {"start": 1221, "end": 1239, "text": "(Xu et al., 2020a)", "ref_id": null}], "ref_spans": [{"start": 595, "end": 806, "text": "a variety of immune cells  20  and improves the immunity, while IFN-\u03b2 takes effect by inhibiting the adsorption of certain  1   viruses, enhancing phagocytosis of natural killer cells and mononuclear macrophages", "ref_id": "TABREF1"}], "section": "Glucocorticoids (GCs) 4"}, {"text": "for the treatment of patients with extensive lung lesions or laboratory tests for elevated IL-6 8 levels (Antinori et al., 2020). In addition, tocilizumab combined with other drugs has been 9 applied in more than 20 countries including Italy (Toniati et al., 2020). 10", "cite_spans": [], "ref_spans": [], "section": "Glucocorticoids (GCs) 4"}, {"text": "The convalescent plasma donated by patients recovered from COVD-19 contains a high 12 titer of specific antibody to SARS-CoV-2, which may mediate a strong passive immunity well tolerated, and patients who received plasma transfusion were improved in terms of 20 several parameters, including lymphocyte counts and C-reactive protein. In addition, no 1 severe adverse effects were observed (Duan et al., 2020) . Serological findings showed that 2 the plasma from six donors recovered from COVID-19 had high IgG titers (above 1:320), 3 and patients who received plasma transfusion showed no related adverse event and did not 4 require mechanical ventilation 11 days after plasma transfusion (Zhang et al., 2020b) . 5", "cite_spans": [{"start": 389, "end": 408, "text": "(Duan et al., 2020)", "ref_id": null}, {"start": 689, "end": 710, "text": "(Zhang et al., 2020b)", "ref_id": null}], "ref_spans": [], "section": "Convalescent plasma product of COVID-19 11"}, {"text": "Though several cured cases have been reported, more expanded clinical trials remains to be 6 fufilled. 7 authorization for the treatment of adults and children with severe COVID-19 disease 20 (Hendaus, 2020) . Though remdesivir was considered as a promising option for COVID-19, 21 17 its safety and effect in humans still requires more evidence from additionalclinical trials (Li 1 et al., 2020). ", "cite_spans": [{"start": 192, "end": 207, "text": "(Hendaus, 2020)", "ref_id": "BIBREF47"}, {"start": 282, "end": 284, "text": "17", "ref_id": null}, {"start": 377, "end": 382, "text": "(Li 1", "ref_id": null}], "ref_spans": [], "section": "Convalescent plasma product of COVID-19 11"}, {"text": "Abundant studies on acute lung injury caused by highly pathogenic viruses, such as 2 influenza A virus and coronavirus, have found that overactivation of complement 3 (especially C5a) may be the central event in that process (Wang et al., 2015) . Therefore, C5a 4 is highly valued as a rational target for the treatment of highly pathogenic virus-mediated 5 acute lung injury. ", "cite_spans": [{"start": 225, "end": 244, "text": "(Wang et al., 2015)", "ref_id": "BIBREF110"}], "ref_spans": [], "section": "Human C5 monoclonal antibody 1"}, {"text": "Most of the promising drugs described above are small molecule drugs, but biological 8 products with specific targeting abilities and less side effects are gradually attracting 9", "cite_spans": [], "ref_spans": [], "section": "Conclusion 7"}, {"text": "interests. The mechanisms underlying the therapies for COVID-19 that have been approved 10 for clinical use or are being evaluated in clinical trials include blocking viral replication, 11 regulation of immune function, reducing inflammatory response and alleviating lung 12 injury (Table 1) Medical University) for their linguistic assistance during the revison of this manuscript. 11", "cite_spans": [], "ref_spans": [{"start": 282, "end": 291, "text": "(Table 1)", "ref_id": "TABREF1"}], "section": "Conclusion 7"}, {"text": "The authors declare no competing interests. ", "cite_spans": [], "ref_spans": [], "section": "Competing interests 12"}], "bib_entries": {"BIBREF1": {"ref_id": "b1", "title": "Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the 3", "authors": [{"first": "J", "middle": ["Y"], "last": "Jordan", "suffix": ""}, {"first": "R", "middle": [], "last": "", "suffix": ""}], "year": 2018, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "Viral Polymerase and the Proofreading Exoribonuclease", "authors": [], "year": null, "venue": "Mbio", "volume": "9", "issn": "", "pages": "221--00218", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment 5 of acute respiratory distress syndrome", "authors": [{"first": "N", "middle": [], "last": "Aikawa", "suffix": ""}, {"first": "Y", "middle": [], "last": "Kawasaki", "suffix": ""}], "year": 2014, "venue": "Ther Clin Risk Manag", "volume": "10", "issn": "", "pages": "621--629", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Coronaviruses -drug discovery and therapeutic 7 options", "authors": [{"first": "", "middle": [], "last": "Alimuddin", "suffix": ""}, {"first": "", "middle": [], "last": "Zumla", "suffix": ""}, {"first": "", "middle": [], "last": "Jasper", "suffix": ""}, {"first": "", "middle": [], "last": "Chan", "suffix": ""}, {"first": "", "middle": [], "last": "Esam", "suffix": ""}, {"first": "David", "middle": [], "last": "Azhar", "suffix": ""}], "year": 2016, "venue": "Nature Reviews Drug Discovery", "volume": "15", "issn": "", "pages": "327--347", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Physiological Functions of Glucocorticoids in Stress and Their 9 Relation to Pharmacological Actions*", "authors": [{"first": "M", "middle": [], "last": "Allan", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Guyre", "suffix": ""}, {"first": "N", "middle": ["J"], "last": "Holbrook", "suffix": ""}], "year": 1984, "venue": "Endocrine Reviews", "volume": "5", "issn": "", "pages": "25--44", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Supportive Treatment with Tocilizumab for COVID-19: A Systematic 11", "authors": [{"first": "S", "middle": ["K"], "last": "Alzghari", "suffix": ""}, {"first": "V", "middle": ["S"], "last": "Acuna", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an 15 increased risk for candidemia? Autoimmunity reviews", "authors": [{"first": "P", "middle": [], "last": "Sarzi-Puttini", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Ridolfo", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "Combined Inhibition of Complement 18 (C5) and CD14 Markedly Attenuates Inflammation, Thrombogenicity, and Hemodynamic Changes in Porcine 19", "authors": [{"first": "A", "middle": ["K"], "last": "Bongoni", "suffix": ""}, {"first": "R", "middle": [], "last": "Rieben", "suffix": ""}, {"first": "M", "middle": [], "last": "Nunn", "suffix": ""}, {"first": "H", "middle": [], "last": "Scott", "suffix": ""}, {"first": "T", "middle": ["E"], "last": "Mollnes", "suffix": ""}], "year": 2013, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF14": {"ref_id": "b14", "title": "Hydroxychloroquine: from malaria to autoimmunity", "authors": [{"first": "I", "middle": [], "last": "Ben-Zvi", "suffix": ""}, {"first": "S", "middle": [], "last": "Kivity", "suffix": ""}, {"first": "P", "middle": [], "last": "Langevitz", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shoenfeld", "suffix": ""}], "year": 2012, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF16": {"ref_id": "b16", "title": "MERS-CoV infection", "authors": [], "year": null, "venue": "P Natl Acad Sci", "volume": "117", "issn": "", "pages": "6771--6776", "other_ids": {}}, "BIBREF19": {"ref_id": "b19", "title": "Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika 5 Virus Infection in Different Cell Models", "authors": [{"first": "A", "middle": [], "last": "Savarino", "suffix": ""}, {"first": "L", "middle": [], "last": "Campanati", "suffix": ""}, {"first": "A", "middle": [], "last": "Tanuri", "suffix": ""}], "year": 2016, "venue": "Viruses", "volume": "8", "issn": "", "pages": "", "other_ids": {}}, "BIBREF20": {"ref_id": "b20", "title": "Arbidol combined with LPV/r 7 versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study", "authors": [{"first": "L", "middle": [], "last": "Deng", "suffix": ""}, {"first": "C", "middle": [], "last": "Li", "suffix": ""}, {"first": "Q", "middle": [], "last": "Zeng", "suffix": ""}, {"first": "X", "middle": [], "last": "Liu", "suffix": ""}, {"first": "X", "middle": [], "last": "Li", "suffix": ""}, {"first": "H", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "Z", "middle": [], "last": "Hong", "suffix": ""}, {"first": "J", "middle": [], "last": "Xia", "suffix": ""}], "year": 2020, "venue": "The Journal of infection", "volume": "8", "issn": "", "pages": "", "other_ids": {}}, "BIBREF22": {"ref_id": "b22", "title": "Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for", "authors": [{"first": "Y", "middle": ["X"], "last": "Du", "suffix": ""}, {"first": "X", "middle": ["P"], "last": "Chen", "suffix": ""}], "year": 2019, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF28": {"ref_id": "b28", "title": "Effectiveness of convalescent plasma therapy in severe COVID-19 patients", "authors": [{"first": "X", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "X", "middle": [], "last": "Yang", "suffix": ""}], "year": 2020, "venue": "16 Proceedings of the National Academy of Sciences", "volume": "117", "issn": "", "pages": "", "other_ids": {}}, "BIBREF29": {"ref_id": "b29", "title": "Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA 18 dependent RNA polymerase (RdRp): A molecular docking study", "authors": [{"first": "A", "middle": ["A"], "last": "Elfiky", "suffix": ""}], "year": 2020, "venue": "Life sciences", "volume": "253", "issn": "", "pages": "", "other_ids": {}}, "BIBREF30": {"ref_id": "b30", "title": "Clinical 20 Features of COVID-19-Related Liver Functional Abnormality", "authors": [{"first": "Z", "middle": [], "last": "Fan", "suffix": ""}, {"first": "L", "middle": [], "last": "Chen", "suffix": ""}, {"first": "J", "middle": [], "last": "Li", "suffix": ""}, {"first": "X", "middle": [], "last": "Cheng", "suffix": ""}, {"first": "J", "middle": [], "last": "Yang", "suffix": ""}, {"first": "C", "middle": [], "last": "Tian", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "S", "middle": [], "last": "Huang", "suffix": ""}, {"first": "Z", "middle": [], "last": "Liu", "suffix": ""}, {"first": "J", "middle": [], "last": "Cheng", "suffix": ""}], "year": 2020, "venue": "Clin Gastroenterol Hepatol", "volume": "18", "issn": "", "pages": "1561--1566", "other_ids": {}}, "BIBREF31": {"ref_id": "b31", "title": "ADMET modeling approaches in drug discovery", "authors": [{"first": "L", "middle": ["L G"], "last": "Ferreira", "suffix": ""}, {"first": "A", "middle": ["D"], "last": "Andricopulo", "suffix": ""}], "year": 2019, "venue": "Drug discovery", "volume": "22", "issn": "", "pages": "1157--1165", "other_ids": {}}, "BIBREF32": {"ref_id": "b32", "title": "Why tocilizumab could be an effective treatment for severe COVID-19?", "authors": [{"first": "B", "middle": [], "last": "Fu", "suffix": ""}, {"first": "X", "middle": [], "last": "Xu", "suffix": ""}, {"first": "H", "middle": [], "last": "Wei", "suffix": ""}], "year": 2020, "venue": "J", "volume": "24", "issn": "", "pages": "", "other_ids": {}}, "BIBREF34": {"ref_id": "b34", "title": "Favipiravir (T-705), a 26 novel viral RNA polymerase inhibitor", "authors": [{"first": "Y", "middle": [], "last": "Furuta", "suffix": ""}, {"first": "B", "middle": ["B"], "last": "Gowen", "suffix": ""}, {"first": "K", "middle": [], "last": "Takahashi", "suffix": ""}, {"first": "K", "middle": [], "last": "Shiraki", "suffix": ""}, {"first": "D", "middle": ["F"], "last": "Smee", "suffix": ""}, {"first": "D", "middle": ["L"], "last": "Barnard", "suffix": ""}], "year": 2013, "venue": "Antiviral research", "volume": "100", "issn": "", "pages": "446--454", "other_ids": {}}, "BIBREF36": {"ref_id": "b36", "title": "T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral 29 infections", "authors": [{"first": "J", "middle": ["D"], "last": "Morrey", "suffix": ""}], "year": 2009, "venue": "Antiviral research", "volume": "82", "issn": "", "pages": "95--102", "other_ids": {}}, "BIBREF39": {"ref_id": "b39", "title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of 33 an open-label non-randomized clinical trial", "authors": [{"first": "P", "middle": [], "last": "Brouqui", "suffix": ""}, {"first": "D", "middle": [], "last": "Raoult", "suffix": ""}], "year": 2020, "venue": "International journal of antimicrobial agents", "volume": "", "issn": "", "pages": "105949--105949", "other_ids": {}}, "BIBREF41": {"ref_id": "b41", "title": "Observational Study of Hydroxychloroquine in Hospitalized 36 Patients with Covid-19", "authors": [{"first": "R", "middle": ["G"], "last": "Sobieszczyk", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Schluger", "suffix": ""}, {"first": "N", "middle": ["W"], "last": "", "suffix": ""}], "year": 2020, "venue": "New England Journal of Medicine", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1056/NEJMoa2012410"]}}, "BIBREF42": {"ref_id": "b42", "title": "Biochemistry and clinical applications of ribavirin. Antimicrobial agents and 38 chemotherap,y 30", "authors": [{"first": "B", "middle": ["E"], "last": "Gilbert", "suffix": ""}, {"first": "V", "middle": [], "last": "Knight", "suffix": ""}], "year": 1986, "venue": "", "volume": "", "issn": "", "pages": "201--205", "other_ids": {}}, "BIBREF43": {"ref_id": "b43", "title": "Mesenchymal Stem Cell Therapy for COVID-19: 40 Present or Future", "authors": [{"first": "A", "middle": [], "last": "Golchin", "suffix": ""}, {"first": "E", "middle": [], "last": "Seyedjafari", "suffix": ""}, {"first": "A", "middle": [], "last": "Ardeshirylajimi", "suffix": ""}], "year": 2020, "venue": "Stem cell reviews and reports", "volume": "", "issn": "", "pages": "1--7", "other_ids": {}}, "BIBREF44": {"ref_id": "b44", "title": "The antiviral compound remdesivir 1 potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. The 2", "authors": [{"first": "C", "middle": ["J"], "last": "Gordon", "suffix": ""}, {"first": "E", "middle": ["P"], "last": "Tchesnokov", "suffix": ""}, {"first": "J", "middle": ["Y"], "last": "Feng", "suffix": ""}, {"first": "D", "middle": ["P"], "last": "Porter", "suffix": ""}, {"first": "M", "middle": [], "last": "Gotte", "suffix": ""}], "year": 2020, "venue": "Journal of biological chemistry", "volume": "295", "issn": "", "pages": "4773--4779", "other_ids": {}}, "BIBREF45": {"ref_id": "b45", "title": "Return of the Coronavirus: 2019-nCoV", "authors": [{"first": "L", "middle": ["E"], "last": "Gralinski", "suffix": ""}, {"first": "V", "middle": ["D"], "last": "Menachery", "suffix": ""}], "year": 2020, "venue": "Viruses", "volume": "12", "issn": "", "pages": "", "other_ids": {}}, "BIBREF46": {"ref_id": "b46", "title": "ADMET in silico modelling: towards prediction paradise?", "authors": [{"first": "V", "middle": ["D W"], "last": "Han", "suffix": ""}, {"first": "E", "middle": [], "last": "Gifford", "suffix": ""}], "year": 2003, "venue": "Nature Reviews 5 Drug Discovery", "volume": "2", "issn": "", "pages": "278--288", "other_ids": {}}, "BIBREF47": {"ref_id": "b47", "title": "Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19): A simplified 7 summary", "authors": [{"first": "M", "middle": ["A"], "last": "Hendaus", "suffix": ""}], "year": 2020, "venue": "Journal of biomolecular structure & dynamics", "volume": "", "issn": "", "pages": "1--6", "other_ids": {"DOI": ["10.1080/07391102.2020.1767691"]}}, "BIBREF51": {"ref_id": "b51", "title": "First Case of 2019 Novel Coronavirus in the United States", "authors": [{"first": "V", "middle": ["C I"], "last": "", "suffix": ""}], "year": 2020, "venue": "New England Journal of Medicine", "volume": "13", "issn": "", "pages": "929--936", "other_ids": {}}, "BIBREF54": {"ref_id": "b54", "title": "Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of 18 chloroquine for the treatment of COVID-19. medRxiv", "authors": [{"first": "R", "middle": [], "last": "Sun", "suffix": ""}, {"first": "Z", "middle": [], "last": "Hong", "suffix": ""}, {"first": "J", "middle": [], "last": "Liu", "suffix": ""}, {"first": "H", "middle": [], "last": "Chen", "suffix": ""}, {"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Z", "middle": [], "last": "Li", "suffix": ""}, {"first": "D", "middle": [], "last": "Pei", "suffix": ""}, {"first": "L", "middle": [], "last": "Tian", "suffix": ""}, {"first": "J", "middle": [], "last": "Xia", "suffix": ""}, {"first": "S", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "N", "middle": [], "last": "Zhong", "suffix": ""}, {"first": "H", "middle": [], "last": "Shan", "suffix": ""}], "year": 2004, "venue": "", "volume": "17", "issn": "", "pages": "", "other_ids": {}}, "BIBREF55": {"ref_id": "b55", "title": "Principles of early drug discovery", "authors": [{"first": "J", "middle": ["P"], "last": "Hughes", "suffix": ""}, {"first": "S", "middle": [], "last": "Rees", "suffix": ""}, {"first": "S", "middle": ["B"], "last": "Kalindjian", "suffix": ""}, {"first": "K", "middle": ["L"], "last": "Philpott", "suffix": ""}], "year": 2011, "venue": "British journal 20 of pharmacology", "volume": "162", "issn": "", "pages": "1239--1249", "other_ids": {}}, "BIBREF60": {"ref_id": "b60", "title": "Triple combination of interferon beta-1b, 26 lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an 27 open-label, randomised, phase 2 trial", "authors": [{"first": "T", "middle": ["L"], "last": "Lau", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Chan", "suffix": ""}, {"first": "K", "middle": ["H"], "last": "To", "suffix": ""}, {"first": "K", "middle": ["K"], "last": "Yuen", "suffix": ""}, {"first": "K", "middle": ["Y"], "last": "", "suffix": ""}], "year": 2020, "venue": "Lancet", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/S0140-6736(20)31042-4"]}}, "BIBREF62": {"ref_id": "b62", "title": "Effect of Neutrophil Elastase Inhibitor (Sivelestat Sodium) in the Treatment of Acute Lung Injury (ALI) and 30", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF63": {"ref_id": "b63", "title": "Acute Respiratory Distress Syndrome (ARDS): A Systematic Review and Meta-Analysis. Internal medicine", "authors": [], "year": null, "venue": "", "volume": "31", "issn": "", "pages": "2423--2432", "other_ids": {}}, "BIBREF64": {"ref_id": "b64", "title": "Structural basis of influenza virus fusion inhibition by the antiviral drug 33", "authors": [{"first": "R", "middle": ["U"], "last": "Kadam", "suffix": ""}, {"first": "I", "middle": ["A"], "last": "Wilson", "suffix": ""}], "year": 2017, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF66": {"ref_id": "b66", "title": "Coronaviruses pathogenesis, comorbidities and 35 multi-organ damage -A review", "authors": [{"first": "Kaviyarasi", "middle": [], "last": "Renu", "suffix": ""}, {"first": "P", "middle": ["L"], "last": "Prasanna", "suffix": ""}, {"first": "V", "middle": ["G"], "last": "Abilash", "suffix": ""}], "year": 2020, "venue": "Life sciences", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.lfs.2020.117839"]}}, "BIBREF67": {"ref_id": "b67", "title": "Novel coronavirus treatment with ribavirin: 37 Groundwork for an evaluation concerning COVID-19", "authors": [{"first": "J", "middle": ["S"], "last": "Khalili", "suffix": ""}, {"first": "H", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "N", "middle": ["S A"], "last": "Mak", "suffix": ""}, {"first": "Y", "middle": [], "last": "Yan", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhu", "suffix": ""}], "year": 2020, "venue": "J Med Virol", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1002/jmv.25798"]}}, "BIBREF68": {"ref_id": "b68", "title": "Potential repurposing of Favipiravir in COVID-19 outbreak based on 39 current evidence. Travel medicine and infectious disease", "authors": [{"first": "K", "middle": [], "last": "Khambholja", "suffix": ""}, {"first": "D", "middle": [], "last": "Asudani", "suffix": ""}], "year": 2020, "venue": "", "volume": "101710", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1002/jmv.25798"]}}, "BIBREF73": {"ref_id": "b73", "title": "Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia", "authors": [], "year": null, "venue": "Aging Dis", "volume": "11", "issn": "", "pages": "216--228", "other_ids": {}}, "BIBREF74": {"ref_id": "b74", "title": "Rapid review for the anti-coronavirus effect of 6 remdesivir", "authors": [{"first": "Z", "middle": [], "last": "Li", "suffix": ""}, {"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "D", "middle": [], "last": "Cao", "suffix": ""}, {"first": "R", "middle": [], "last": "Sun", "suffix": ""}, {"first": "C", "middle": [], "last": "Li", "suffix": ""}, {"first": "G", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "Drug discoveries & therapeutics", "volume": "14", "issn": "", "pages": "73--76", "other_ids": {}}, "BIBREF76": {"ref_id": "b76", "title": "Persistence 9 and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients", "authors": [{"first": "Chen", "middle": [], "last": "Jun", "suffix": ""}, {"first": "Hu", "middle": [], "last": "Bijie", "suffix": ""}, {"first": "Wang", "middle": [], "last": "Sheng", "suffix": ""}, {"first": "Mao", "middle": [], "last": "Enqiang", "suffix": ""}, {"first": "Zhu", "middle": [], "last": "Lei", "suffix": ""}, {"first": "Zhang", "middle": [], "last": "Wenhong", "suffix": ""}, {"first": "L", "middle": [], "last": "Hongzhou", "suffix": ""}], "year": 2020, "venue": "Chin Med J (Engl)", "volume": "133", "issn": "", "pages": "10--1039", "other_ids": {}}, "BIBREF77": {"ref_id": "b77", "title": "New developments in the induction and antiviral effectors of type I 12 interferon", "authors": [{"first": "S", "middle": ["Y"], "last": "Liu", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Sanchez", "suffix": ""}, {"first": "G", "middle": [], "last": "Cheng", "suffix": ""}], "year": 2011, "venue": "Current Opinion in Immunology", "volume": "23", "issn": "", "pages": "57--64", "other_ids": {}}, "BIBREF79": {"ref_id": "b79", "title": "Inhibition of hepatitis C virus replication by chloroquine 15 targeting virus-associated autophagy", "authors": [{"first": "T", "middle": [], "last": "Sakai", "suffix": ""}, {"first": "E", "middle": [], "last": "Kominami", "suffix": ""}, {"first": "S", "middle": [], "last": "Watanabe", "suffix": ""}], "year": 2010, "venue": "J Gastroenterol", "volume": "45", "issn": "", "pages": "195--203", "other_ids": {}}, "BIBREF80": {"ref_id": "b80", "title": "Mesenchymal stem cell derived secretome and 17 extracellular vesicles for acute lung injury and other inflammatory lung diseases", "authors": [{"first": "A", "middle": [], "last": "Monsel", "suffix": ""}, {"first": "Y", "middle": ["G"], "last": "Zhu", "suffix": ""}, {"first": "V", "middle": [], "last": "Gudapati", "suffix": ""}, {"first": "H", "middle": [], "last": "Lim", "suffix": ""}, {"first": "J", "middle": ["W"], "last": "Lee", "suffix": ""}], "year": 2016, "venue": "Expert Opin Biol Ther", "volume": "16", "issn": "", "pages": "859--871", "other_ids": {}}, "BIBREF81": {"ref_id": "b81", "title": "Type I interferons produced by 20 dendritic cells promote their phenotypic and functional activation", "authors": [{"first": "M", "middle": [], "last": "Montoya", "suffix": ""}, {"first": "G", "middle": [], "last": "Schiavoni", "suffix": ""}, {"first": "F", "middle": [], "last": "Mattei", "suffix": ""}, {"first": "I", "middle": [], "last": "Gresser", "suffix": ""}, {"first": "D", "middle": ["F"], "last": "Tough", "suffix": ""}], "year": 2002, "venue": "Blood", "volume": "99", "issn": "", "pages": "3263--3271", "other_ids": {}}, "BIBREF82": {"ref_id": "b82", "title": "Successful treatment 22 of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model", "authors": [{"first": "L", "middle": [], "last": "Oestereich", "suffix": ""}, {"first": "A", "middle": [], "last": "Luedtke", "suffix": ""}, {"first": "S", "middle": [], "last": "Wurr", "suffix": ""}, {"first": "T", "middle": [], "last": "Rieger", "suffix": ""}, {"first": "C", "middle": [], "last": "Munoz-Fontela", "suffix": ""}, {"first": "S", "middle": [], "last": "Guenther", "suffix": ""}], "year": 2014, "venue": "Antiviral research", "volume": "105", "issn": "", "pages": "23--40", "other_ids": {}}, "BIBREF84": {"ref_id": "b84", "title": "Ribavirin and interferon alfa-2a for severe Middle East 26 respiratory syndrome coronavirus infection: a retrospective cohort study", "authors": [{"first": "M", "middle": ["M"], "last": "Albarrak", "suffix": ""}, {"first": "Z", "middle": ["A"], "last": "Memish", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Albarrak", "suffix": ""}], "year": 2014, "venue": "Lancet Infectious Diseases", "volume": "14", "issn": "", "pages": "1090--1095", "other_ids": {}}, "BIBREF85": {"ref_id": "b85", "title": "New uses for old drugs", "authors": [{"first": "P", "middle": [], "last": "Pan", "suffix": ""}, {"first": "P", "middle": [], "last": "Munir", "suffix": ""}, {"first": "M", "middle": [], "last": "Nasir", "suffix": ""}], "year": 2018, "venue": "Bmj Clinical Research", "volume": "361", "issn": "", "pages": "", "other_ids": {}}, "BIBREF86": {"ref_id": "b86", "title": "Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol", "authors": [{"first": "E.-I", "middle": [], "last": "P\u00e9cheur", "suffix": ""}, {"first": "D", "middle": [], "last": "Lavillette", "suffix": ""}, {"first": "F", "middle": [], "last": "Alcaras", "suffix": ""}, {"first": "J", "middle": [], "last": "Molle", "suffix": ""}, {"first": "Y", "middle": ["S"], "last": "Boriskin", "suffix": ""}, {"first": "M", "middle": [], "last": "Roberts", "suffix": ""}, {"first": "F.-L", "middle": [], "last": "Cosset", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Polyak", "suffix": ""}], "year": 2007, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF88": {"ref_id": "b88", "title": "Effectiveness of 33 glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled 34 trial", "authors": [{"first": "Y", "middle": ["Y"], "last": "Qin", "suffix": ""}, {"first": "Y", "middle": ["H"], "last": "Zhou", "suffix": ""}, {"first": "Y", "middle": ["Q"], "last": "Lu", "suffix": ""}, {"first": "F", "middle": [], "last": "Sun", "suffix": ""}, {"first": "S", "middle": [], "last": "Yang", "suffix": ""}, {"first": "V", "middle": [], "last": "Harypursat", "suffix": ""}, {"first": "Y", "middle": ["K"], "last": "Chen", "suffix": ""}], "year": 2020, "venue": "Chin Med J (Engl)", "volume": "133", "issn": "", "pages": "1080--1086", "other_ids": {}}, "BIBREF89": {"ref_id": "b89", "title": "Antiinflammatory Action of Glucocorticoids -New Mechanisms for Old 36", "authors": [{"first": "T", "middle": [], "last": "Rhen", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Cidlowski", "suffix": ""}], "year": 2005, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF91": {"ref_id": "b91", "title": "Baricitinib as 38 potential treatment for 2019-nCoV acute respiratory disease", "authors": [{"first": "P", "middle": [], "last": "Richardson", "suffix": ""}, {"first": "I", "middle": [], "last": "Griffin", "suffix": ""}, {"first": "C", "middle": [], "last": "Tucker", "suffix": ""}, {"first": "D", "middle": [], "last": "Smith", "suffix": ""}, {"first": "O", "middle": [], "last": "Oechsle", "suffix": ""}, {"first": "A", "middle": [], "last": "Phelan", "suffix": ""}, {"first": "J", "middle": [], "last": "Stebbing", "suffix": ""}], "year": 2020, "venue": "Lancet", "volume": "395", "issn": "", "pages": "30--31", "other_ids": {}}, "BIBREF92": {"ref_id": "b92", "title": "Favipiravir 40 (T-705) inhibits in vitro norovirus replication", "authors": [{"first": "J", "middle": [], "last": "Rocha-Pereira", "suffix": ""}, {"first": "D", "middle": [], "last": "Jochmans", "suffix": ""}, {"first": "K", "middle": [], "last": "Dallmeier", "suffix": ""}, {"first": "P", "middle": [], "last": "Leyssen", "suffix": ""}, {"first": "M", "middle": ["S J"], "last": "Nascimento", "suffix": ""}, {"first": "J", "middle": [], "last": "Neyts", "suffix": ""}], "year": 2012, "venue": "Biochem Biophys Res Commun", "volume": "424", "issn": "", "pages": "777--780", "other_ids": {}}, "BIBREF93": {"ref_id": "b93", "title": "Encouraging New Uses for Old Drugs", "authors": [{"first": "R", "middle": ["E"], "last": "Sachs", "suffix": ""}, {"first": "P", "middle": ["B"], "last": "Ginsburg", "suffix": ""}, {"first": "D", "middle": ["P"], "last": "Goldman", "suffix": ""}], "year": 2017, "venue": "JAMA", "volume": "318", "issn": "", "pages": "2421--2422", "other_ids": {}}, "BIBREF94": {"ref_id": "b94", "title": "Mechanisms involved in the side effects of glucocorticoids", "authors": [{"first": "H", "middle": [], "last": "Sch\u00e4cke", "suffix": ""}, {"first": "W", "middle": ["D"], "last": "D\u00f6cke", "suffix": ""}, {"first": "K", "middle": [], "last": "Asadullah", "suffix": ""}], "year": 2002, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF97": {"ref_id": "b97", "title": "The Lysosomotropic Amines, Chloroquine and Hydroxychloroquine: A 7 Potentially Novel Therapy for Graft-Versus-Host Disease", "authors": [{"first": "K", "middle": ["R"], "last": "Schultz", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Gilman", "suffix": ""}], "year": 1997, "venue": "Leukemia & lymphoma", "volume": "24", "issn": "", "pages": "201--210", "other_ids": {}}, "BIBREF99": {"ref_id": "b99", "title": "Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 10 Exonuclease active-sites", "authors": [{"first": "F", "middle": [], "last": "Canard", "suffix": ""}, {"first": "B", "middle": [], "last": "", "suffix": ""}], "year": 2020, "venue": "Antiviral research", "volume": "178", "issn": "", "pages": "", "other_ids": {}}, "BIBREF100": {"ref_id": "b100", "title": "Mechanism of Inhibition of Ebola Virus 12 RNA-Dependent RNA Polymerase by Remdesivir", "authors": [{"first": "E", "middle": [], "last": "Tchesnokov", "suffix": ""}, {"first": "J", "middle": [], "last": "Feng", "suffix": ""}, {"first": "D", "middle": [], "last": "Porter", "suffix": ""}, {"first": "M", "middle": [], "last": "G\u00f6tte", "suffix": ""}], "year": 2019, "venue": "Viruses", "volume": "11", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3390/v11040326"]}}, "BIBREF102": {"ref_id": "b102", "title": "Tocilizumab for the treatment of severe 15 COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study 16 of 100 patients in Brescia", "authors": [{"first": "N", "middle": [], "last": "Latronico", "suffix": ""}, {"first": "R", "middle": [], "last": "Brescia International", "suffix": ""}, {"first": "H", "middle": ["U B"], "last": "Training", "suffix": ""}], "year": 2020, "venue": "Italy. Autoimmunity reviews", "volume": "19", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.autrev.2020.102568"]}}, "BIBREF104": {"ref_id": "b104", "title": "Evaluation of Convalescent Plasma for Ebola Virus Disease", "authors": [{"first": "H", "middle": [], "last": "Magassouba", "suffix": ""}, {"first": "N", "middle": ["F"], "last": "Antierens", "suffix": ""}, {"first": "A", "middle": [], "last": "", "suffix": ""}], "year": 2016, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF106": {"ref_id": "b106", "title": "Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the 22 trimerization of viral spike glycoprotein ?", "authors": [{"first": "N", "middle": [], "last": "Vankadari", "suffix": ""}], "year": 2020, "venue": "International journal of antimicrobial agents", "volume": "105998", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.ijantimicag.2020.105998"]}}, "BIBREF107": {"ref_id": "b107", "title": "Structure, Function, and 25 Antigenicity of the SARS-CoV-2 Spike Glycoprotein", "authors": [{"first": "A", "middle": ["C"], "last": "Walls", "suffix": ""}, {"first": "Y.-J", "middle": [], "last": "Park", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Tortorici", "suffix": ""}, {"first": "A", "middle": [], "last": "Wall", "suffix": ""}, {"first": "A", "middle": ["T"], "last": "Mcguire", "suffix": ""}, {"first": "D", "middle": [], "last": "Veesler", "suffix": ""}], "year": 2020, "venue": "Cell", "volume": "181", "issn": "", "pages": "281--292", "other_ids": {}}, "BIBREF109": {"ref_id": "b109", "title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. 28 Cell research", "authors": [], "year": null, "venue": "", "volume": "30", "issn": "", "pages": "269--271", "other_ids": {}}, "BIBREF110": {"ref_id": "b110", "title": "The role of C5a in acute lung injury induced by highly 30 pathogenic viral infections", "authors": [{"first": "R", "middle": [], "last": "Wang", "suffix": ""}, {"first": "H", "middle": [], "last": "Xiao", "suffix": ""}, {"first": "R", "middle": [], "last": "Guo", "suffix": ""}, {"first": "Y", "middle": [], "last": "Li", "suffix": ""}, {"first": "B", "middle": [], "last": "Shen", "suffix": ""}], "year": 2015, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF112": {"ref_id": "b112", "title": "The anti-influenza virus drug, arbidol is an efficient inhibitor of 33 SARS-CoV-2 in vitro", "authors": [{"first": "F", "middle": [], "last": "Hu", "suffix": ""}, {"first": "Z", "middle": [], "last": "Zhong", "suffix": ""}, {"first": "W", "middle": [], "last": "Wang", "suffix": ""}, {"first": "M", "middle": [], "last": "", "suffix": ""}], "year": 2020, "venue": "Cell discovery", "volume": "6", "issn": "", "pages": "", "other_ids": {}}, "BIBREF117": {"ref_id": "b117", "title": "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF119": {"ref_id": "b119", "title": "Glucocorticoids and immune function: Unknown dimensions and new frontiers", "authors": [{"first": "T", "middle": [], "last": "Wilckens", "suffix": ""}, {"first": "R", "middle": ["D"], "last": "Rijk", "suffix": ""}], "year": 1997, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF122": {"ref_id": "b122", "title": "Effective treatment of severe COVID-19 patients with tocilizumab", "authors": [{"first": "H", "middle": [], "last": "Wei", "suffix": ""}], "year": 2020, "venue": "Proc Natl Acad Sci U S A", "volume": "4", "issn": "", "pages": "10970--10975", "other_ids": {}}, "BIBREF124": {"ref_id": "b124", "title": "Pathological findings of COVID-19 7 associated with acute respiratory distress syndrome", "authors": [{"first": "T", "middle": [], "last": "Gao", "suffix": ""}, {"first": "J", "middle": [], "last": "Song", "suffix": ""}, {"first": "P", "middle": [], "last": "Xia", "suffix": ""}, {"first": "J", "middle": [], "last": "Dong", "suffix": ""}, {"first": "J", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "F.-S", "middle": [], "last": "Wang", "suffix": ""}], "year": 2020, "venue": "The Lancet Respiratory Medicine", "volume": "8", "issn": "", "pages": "420--422", "other_ids": {}}, "BIBREF126": {"ref_id": "b126", "title": "Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 10 2019", "authors": [{"first": "Z", "middle": ["W"], "last": "Ruan", "suffix": ""}, {"first": "L", "middle": [], "last": "Hong", "suffix": ""}], "year": 2020, "venue": "European review for medical and pharmacological sciences", "volume": "24", "issn": "", "pages": "3390--3396", "other_ids": {}}, "BIBREF128": {"ref_id": "b128", "title": "Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir", "authors": [{"first": "Y", "middle": ["C"], "last": "Xie", "suffix": ""}, {"first": "G", "middle": [], "last": "Tian", "suffix": ""}, {"first": "H", "middle": ["W"], "last": "Jiang", "suffix": ""}, {"first": "S", "middle": ["C"], "last": "Tao", "suffix": ""}, {"first": "J", "middle": [], "last": "Shen", "suffix": ""}, {"first": "Y", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "H", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Xu", "suffix": ""}, {"first": "S", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "H", "middle": ["E"], "last": "Xu", "suffix": ""}], "year": null, "venue": "", "volume": "13", "issn": "", "pages": "", "other_ids": {}}, "BIBREF130": {"ref_id": "b130", "title": "COVID-19 pathophysiology: A review", "authors": [{"first": "K", "middle": [], "last": "Yuki", "suffix": ""}, {"first": "M", "middle": [], "last": "Fujiogi", "suffix": ""}, {"first": "S", "middle": [], "last": "Koutsogiannaki", "suffix": ""}], "year": 2020, "venue": "Clin Immunol", "volume": "215", "issn": "", "pages": "16--108427", "other_ids": {}}, "BIBREF131": {"ref_id": "b131", "title": "Application, evaluation and pharmaceutical care of ribavirin in 18 the treatment of viral diseases", "authors": [{"first": "Zehua", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "Qiaoyu", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Z", "middle": [], "last": "Zhao", "suffix": ""}], "year": 2020, "venue": "Chinese Journal of Hospital Pharmacy", "volume": "40", "issn": "", "pages": "721--725", "other_ids": {}}, "BIBREF132": {"ref_id": "b132", "title": "The cytokine release syndrome (CRS) of severe", "authors": [{"first": "C", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "Z", "middle": [], "last": "Wu", "suffix": ""}, {"first": "J", "middle": ["W"], "last": "Li", "suffix": ""}, {"first": "H", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "G", "middle": ["Q"], "last": "Wang", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF133": {"ref_id": "b133", "title": "IL-6R) antagonist Tocilizumab may be the key to reduce the mortality", "authors": [], "year": null, "venue": "COVID-19 and Interleukin-6 receptor", "volume": "21", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.ijantimicag.2020.105954"]}}, "BIBREF135": {"ref_id": "b135", "title": "CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from 25 COVID-19", "authors": [{"first": "Anti-Sars-", "middle": [], "last": "", "suffix": ""}], "year": null, "venue": "Aging", "volume": "12", "issn": "", "pages": "6536--6542", "other_ids": {}}, "BIBREF136": {"ref_id": "b136", "title": "Stem Cell-Based Therapy for Coronavirus Disease", "authors": [{"first": "R", "middle": ["C"], "last": "Zhao", "suffix": ""}], "year": 2019, "venue": "Stem cells and development", "volume": "29", "issn": "", "pages": "27--679", "other_ids": {}}, "BIBREF137": {"ref_id": "b137", "title": "Treatment with Convalescent Plasma for Influenza A (H5N1) Infection", "authors": [{"first": "B", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "N", "middle": [], "last": "Zhong", "suffix": ""}, {"first": "Y", "middle": [], "last": "Guan", "suffix": ""}], "year": 2007, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF139": {"ref_id": "b139", "title": "A potential ex vivo infection model of human 31 induced pluripotent stem cell-3D organoids beyond coronavirus disease 2019", "authors": [{"first": "H", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "L", "middle": ["P"], "last": "Liu", "suffix": ""}, {"first": "M", "middle": [], "last": "Fang", "suffix": ""}, {"first": "Y", "middle": ["M"], "last": "Li", "suffix": ""}, {"first": "Y", "middle": ["W"], "last": "Zheng", "suffix": ""}], "year": 2020, "venue": "Histology and histopathology", "volume": "32", "issn": "18223", "pages": "", "other_ids": {"DOI": ["10.14670/HH-18-223"]}}, "BIBREF140": {"ref_id": "b140", "title": "Arbidol monotherapy is superior to 34 lopinavir/ritonavir in treating COVID-19", "authors": [{"first": "Z", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "Z", "middle": [], "last": "Lu", "suffix": ""}, {"first": "T", "middle": [], "last": "Xu", "suffix": ""}, {"first": "C", "middle": [], "last": "Chen", "suffix": ""}, {"first": "G", "middle": [], "last": "Yang", "suffix": ""}, {"first": "T", "middle": [], "last": "Zha", "suffix": ""}, {"first": "J", "middle": [], "last": "Lu", "suffix": ""}, {"first": "Y", "middle": [], "last": "Xue", "suffix": ""}], "year": 2020, "venue": "The Journal of infection", "volume": "81", "issn": "", "pages": "21--23", "other_ids": {"DOI": ["10.1016/j.jinf.2020.03.060"]}}, "BIBREF141": {"ref_id": "b141", "title": "Reducing mortality from 2019-nCoV: 37 host-directed therapies should be an option", "authors": [{"first": "A", "middle": [], "last": "Zumla", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Hui", "suffix": ""}, {"first": "E", "middle": ["I"], "last": "Azhar", "suffix": ""}, {"first": "Z", "middle": ["A"], "last": "Memish", "suffix": ""}, {"first": "M", "middle": [], "last": "Maeurer", "suffix": ""}], "year": 2020, "venue": "Lancet", "volume": "395", "issn": "", "pages": "35--36", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "thus indirectly conducting the secretion of antiviral proteins in cells (Liu et al.\u03b1 can effectively inhibit the replication of MERS-CoV and SARS-CoV in vitro or in 5 animal models, and it has been used in combination with other antiviral drugs (such as 6 ribavirin) to treat patients with SARS-CoV and MERS-CoV (Omrani et al., 2014). An 7 open-label, randomized, phase II trial concluded that triple antiviral therapy with IFN \u03b2-1b, 8 lopinavir/ritonavir and ribavirin was safe and superior to lopinavir/ritonavir alone in 9 shortening virus shedding, and alleviating symptoms of COVID-19 patients (Hung et al., 10 2020). It was also stated that inhaled IFN-\u03b1 can be used as a trial treatment against 11 COVID-19 in the DTPNCP.", "latex": null, "type": "figure"}, "FIGREF1": {"text": "of the peripheral blood samples of severe COVID-19 patients indicated that 14 severe lung injury caused by SARS-CoV-2 was associated with the levated 15 pro-inflammatory cytokine responses. Pathogenic T-cells are rapidly activated by viruses 16 and produce cytokines such as granulocyte-macrophage colony-stimulating factor 17 (GM-CSF) and interleukin 6 (IL-6), which are two key inflammatory factors. The 18 progressive increase of IL-6 has been regarded as a clinical warning indicator of disease 19 deterioration (Alzghari and Acuna, 2020; Fu et al., 2020; Zhang et al., 2020a). 20", "latex": null, "type": "figure"}, "FIGREF2": {"text": "13 against the virus (Cao and Shi, 2020). The plasma products have already been used in the 14 treatment against influenza, SARS and Ebola infection (Burnouf and Radosevich, 2003; Van 15 Griensven et al., 2016; Zhou et al., 2007). 16 Convalescent plasma was listed in the DTPNCP since Trial Version 4. China National 17 Biotec Group launched a research on the convalescent plasma for treatment of COVID-19 18 since January 20. The results indicated that one dose (200 ml) of convalescent plasma was 19", "latex": null, "type": "figure"}, "FIGREF3": {"text": "Avigan\u00ae) is a RdRp inhibitor with broad-spectrum anti-influenza activity 11 (Furuta et al., 2013), developed by Toyama Chemical Industry, and was conditionally 12 licensed in Japan in 2014. Favipiravir can selectively inhibit RNA polymerase related to the 13 replication of the influenza virus and can be phosphoribosylated by host cell enzyme to 14 produce bioactive favipiravir furylribo-5-triphosphate-inositol (favipiravir RTP). Virus RNA 15 polymerase misrecognizes favipiravir RTP, resulting in insertion of favipiravir RTP into the 16 viral RNA chain or its binding to the viral RNA polymerase domain, which hinders the 17 replication and transcription of the RNA chain of the virus (Furuta et al., 2009). Because of 18 the specific mechanism, favipiravir has an inhibitory effect on the Ebola virus, yellow fever 19 virus, norovirus and so on (Furuta et al., 2009; Oestereich et al., 2014; Rocha-Pereira et al., 20 2012). Nowadays, favipiravir has been used in the antiviral treatment of influenza A and B. 21 Besides, the drug-drug interactions and mechanisms of favipiravir against SARSa significant inhibitory effect on SARS-CoV-2 in vitro (EC 50 =61.88\u03bcM) Wang et al., 2020a). On February 16th, favipiravir was approved by the NMPA for the 4 treatment of new or recurrent influenza in adults. Up to now, there are 4 trials of favipiravir 5 for COVID-19 ongoing in China (Khambholja and Asudani, 2020). The preliminary result 6 of a clinical study (ChiCTR2000029600) showed that favipiravir might relieve the 7 progression of COVID-19 by accelerating the virus clearance. Another open-label control 8 study delclared that favipiravir showed significantly better therapeutic effects on the disease 9 progression and viral clearance, with an improvement rate of 91.43% versus 62.22% 10 (P=0.004) in the chest imaging, compared with lopinavir/ritonavir (Cai et al., 2020).", "latex": null, "type": "figure"}, "FIGREF4": {"text": "nucleotide analogue prodrug developed by Gilead, remdesivir can also inhibitRdRp  13    with the same mechanism of action similar to that of favipiravir(Tchesnokov et al., 2019). 14 The structure of RdRp-Remdesivir complex indicates that the partial double-strandedRNA  15    template is inserted into the central channel of RdRp where remdesivir is covalently 16 incorporated into the primer strand at the first replicated base pair, thus terminating the 17 chain elongation(Yin et al., 2020). Once incorporated at position i, the inhibitor causes 18 RNA synthesis arrest at position i+3(Gordon et al., 2020). In addition, the importance of 19 the balance between incorporation and excision properties of nucleoside analogues between 20 the RdRp and exonuclease also received increasing attention(Shannon et al., 2020). In 1 general, remdesivir is a broad-spectrum antiviral candidate drug with the potential against2 many viruses (Agostini et al., 2018; de Wit et al., 2020). 3 On January 31 st , the clinical symptoms of a patient infected with SARS-CoV-2 in the United 4 States were significantly improved after treatment with remdesivir, and the oxygen 5 saturation recovered to 94%-96% (Holshue et al., 2020). Four days later, it was reported 6 that remdesivir had the strongest in vitro inhibitory effect on SARS-CoV-2 among the six 7 tested antiviral drugs (EC 50 =0.77 \u03bcM) (Wang et al., 2020a). A phase \u2162, randomized, 8 double-blind, placebo-controlled multicenter clinical study lasting for 85 days and including 9 237 cases (158 to remdesivir) with mild to moderate SARS-CoV-2 infection 10 (NCT04257656) was conducted in China. The results showed that the use of remdesivir was 11 not associated with a difference in time to clinical improvement, yet patients receiving 12 remdesivir had a significantly faster clinical improvement with symptom duration of 10 13 days or less, and the adverse events were reported in 66%, compared to 64% of the placebo 14 group (Wang et al., 2020c). Morever, the results of a phase \u2162trial revealed by Gilead 15 suggested that remdesivir had a better effect in the 10-day group. Remdesivir was also 16 found to have a synergy effect with emetine, and remdesivir at 6.25 \u03bcM in combination with 17 emetine at 0.195 \u03bcM may achieve 64.9% inhibition in viral yield (Choy et al., 2020). Based 18 on these clinical findings, USFDA has made remdesivir available under an emergency-use 19", "latex": null, "type": "figure"}, "FIGREF5": {"text": "is the first drug to treat acute lung injury caused by systemic 4 inflammatory response syndrome (SIRS), developed by Ono Company in Japan. It was 5 licensed in Japan in April 2002. The low molecular weight enables sivelestat sodium to 6 reach the gap between neutrophils and tissues, and its enzyme inhibitory activity is not 7 affected by reactive oxygen species, which can effectively inhibit neutrophil elastase in the 8 local site of inflammation (Aikawa and Kawasaki, 2014). Sivelestat sodium can improve 9 respiratory function, shortens the time of using respirator, reduces the complication rate of 10 stress injury and respiratory infection caused by respirator installation, and improves acute 11 lung injury caused by SIRS and idiopathic pulmonary fibrosis (Iwata et al., 2010). 12 As early as mid-May 2003, NMPA approved the clinical study of sivelestat sodium for the 13 treatment of acute lung injury caused by SARS. Although the phase III clinical trial of 14 sivelestat sodium was completed in 2013, it has not been licensed in China. Aikawa's 15 research on the safety of sivelestat sodium in treating the acute lung injury showed no 16 negative effect in the long-term treatment. On March 12nd, sivelestat sodium was approved 17 by NMPA (CYHS2000102) for the acute lung injury with SIRS and ARDS caused by 18 COVID-19.", "latex": null, "type": "figure"}, "FIGREF6": {"text": "19", "latex": null, "type": "figure"}, "FIGREF7": {"text": "is a monoclonal antibody targeting human C5a developed in China, it can control 7 the further development of inflammation without inhibiting immune function (Barratt-Due 8 et al., 2013). It is expected to prevent the exacerbation of pneumonia in coronavirus 9 infection and further reduce the incidence of severe pneumonia and acute respiratory 10 distress syndrome. BDB-001 injection has been approved by NMPA and is about to enter a 11 phase 1-b clinical trial for the treatment of COVID-19.", "latex": null, "type": "figure"}, "FIGREF8": {"text": "several preclinical studies, mesenchymal stem cell (MSC), which has the 14 characteristics of low immunogenicity and secretion of soluble factors to regulate immune 15 response, plays an important role in attenuating underlying acute lung injury (Monsel et al., 16 2016). Some induced pluripotent stem cells may serve as suitable infection models for drug 17 screening ex vivo (Zhou et al., 2020). In addition, based on the similar pathogenesis and 18 symptoms of H7N9 and COVID-19, MSC transplantation may be a way to improve the 19 symptoms of severe patients with COVID-19 (Chen et al., 2020). 20 Several clinical trials have been conducted to evaluate the safety and effciacy of MSC 21 19 therapy for COVID-19. Studies showed that ACE2 -MSCs could be beneficial for the 1 patients with COVID-19 pneumonia (Leng et al., 2020; Zhao, 2020). Due to the fact that 2 CAStem (Human embryonic stem cell-derived M cells) significantly improved the survival 3 rate in ARDS mice model, CAStem has been approved by NMPA to evaluate the safety and 4 efficacy for severe COVID-19 associated with/without ARDS (Golchin et al., 2020; 5 Kaviyarasi Renu et al., 2020). 6", "latex": null, "type": "figure"}, "FIGREF9": {"text": ". Interfering with the normal replication of genetic material and blocking the 13 formation of viral coat protein granules are two main strategies to block the viral replication. 14 Reducing inflammatory response and alleviating injury can be achieved by inhibiting 15 inflammatory factors or blocking the migration and other active responses of granulocytes. 16While new use of old drugs is the most ideal strategy to identify effective drugs that can be 17 translated to the clinical use immediately, further clinical trials of old drugs to treat 18 COVID-19 are required, since these drugs are not specifically developed based on the 19 pathogenic mechanism of COVID-19. In addition, the strategy of new use of old drugs is 2020    not supposed to be a permanent solution for drug discovery to fight COVID-31400788). We thank Prof. Shan Guan and Miss Xiaoqing Zhan(Third Military 10", "latex": null, "type": "figure"}, "FIGREF11": {"text": ", E.M., Bastiaens, G.J.H., Teirlinck, A.C., van Gemert, G.-J., Graumans, W., van de Vegte-Bolmer, M., 25 Siebelink-Stoter, R., Arens, T., Teelen, K., Nahrendorf, W., Remarque, E.J., Roeffen, W., Jansens, A., 26 Zimmerman, D., Vos, M., van Schaijk, B.C.L., Wiersma, J., van der Ven, A.J.A.M., de Mast, Q., van Lieshout, 27 L., Verweij, J.J., Hermsen, C.C., Scholzen, A., Sauerwein, R.W., 2013. Protection against malaria after 28 immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. M.G.S., Val, F.F.A., Sampaio, V.S., Alexandre, M.A.A., Melo, G.C., Brito, M., Mourao, M.P.G., 31 Brito-Sousa, J.D., Baia-da-Silva, D., Guerra, M.V.F., Hajjar, L.A., Pinto, R.C., Balieiro, A.A.S., Pacheco, 32 A.G.F., Santos, J.D.O., Jr., Naveca, F.G., Xavier, M.S., Siqueira, A.M., Schwarzbold, A., Croda, J., Nogueira, 33 M.L., Romero, G.A.S., Bassat, Q., Fontes, C.J., Albuquerque, B.C., Daniel-Ribeiro, C.T., Monteiro, W.M., 34 Lacerda, M.V.G., CloroCovid, T., 2020. Effect of High vs Low Doses of Chloroquine Diphosphate as 35 Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA, network open 3, e208857. 37 Burnouf, T., Radosevich, M., 2003. Treatment of severe acute respiratory syndrome with convalescent plasma. 38 Hong Kong medical journal, 9, 309-310. 39 C E, S., 2001. Antiviral actions of interferons. Clinical microbiology reviews, 4, 778-809. 40 25 Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., Shen, C., Li, X.B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., 5 Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Yuan, Y., Chen, H., Li, H., Huang, H., Tu, S., 6 Gong, F., Liu, Y., Wei, Y., Dong, C., Zhou, F., Gu, X., Xu, J., Liu, Z., Zhang, Y., Li, H., Shang, L., Wang, K., 7 Li, K., Zhou, X., Dong, X., Qu, Z., Lu, S., Hu, X., Ruan, S., Luo, S., Wu, J., Peng, L., Cheng, F., Pan, L., Zou, 8 J., Jia, C., Wang, J., Liu, X., Wang, S., Wu, X., Ge, Q., He, J., Zhan, H., Qiu, F., Guo, L., Huang, C., Jaki, T., 9 Hayden, F.G., Horby, P.W., Zhang, D., Wang, C., 2020. A Trial of Lopinavir-Ritonavir in Adults Hospitalized 10 with Severe Covid-19. New England Journal of Medicine, 382, 1787-1799.11 Cao, H., Shi, Y., 2020. Convalescent plasma: possible therapy for novel coronavirus disease 2019. J., Hu, C., Chen, L., Tang, L., Zhu, Y., Xu, X., Chen, L., Gao, H., Lu, X., Yu, L., Dai, X., Xiang, C., Li, 14 L., 2020. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by 15 epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment. Engineering, 16 https://doi.org/10.1016/j.eng.2020.02.006. 17 Chen Min, Tong Rongsheng, Bian Yuan, Shu Yongquan, Yang Yong, Du Shan, Li Wenyuan, Xinxia\uff0c, L., Yan 18 Junfeng, Long Enwu, Lin, H., 2020. Evidence-Based Rapid Review on Possibility of Treatment of Novel 19 Coronavirus Pneumonia with Subcutaneous interferon-\u03b1. Herald of Medicine, 39, 483-488.20 Cheng, C.Y., Lee, Y.L., Chen, C.P., Lin, Y.C., Liu, C.E., Liao, C.H., Cheng, S.H., 2020. Lopinavir/ritonavir did 21 not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. Journal of 22 microbiology, immunology, and infection, https://doi.org/10.1016/j.jmii.2020.03.032 . 23 Choy, K.T., Wong, A.Y., Kaewpreedee, P., Sia, S.F., Chen, D., Hui, K.P.Y., Chu, D.K.W., Chan, M.C.W., 24 Cheung, P.P., Huang, X., Peiris, M., Yen, H.L., 2020. Remdesivir, lopinavir, emetine, and homoharringtonine 25 inhibit SARS-CoV-2 replication in vitro. Antiviral research, 178, 104786. 26 Chu, C.M., Cheng, V.C.C., Hung, I.F.N., Wong, M.M.L., Chan, K.H., Chan, K.S., Kao, R.Y.T., Poon, L.L.M., 27 Wong, C.L.P., Guan, Y., Peiris, J.S.M., Yuen, K.Y., 2004. Role of lopinavir/ritonavir in the treatment of SARS: 28 initial virological and clinical findings. Thorax, 59, 252-256. 29 Chunxiao Yang , Shijun Li , Shaojun Shi , Yani Liu, Jiali Zhou, Yu Zhang, Chen Shi, 2020. Rational drug use 30 and pharmaceutical care strategies under COVID-19 epidemic. Chinese Journal of Hospital Pharmacy, 1-7 (in 31 Chinese), http://kns.cnki.net/kcms/detail/42.1204.R.20200317.0934.002.html.32 Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., Einav, S., 2020. A systematic review on the efficacy 33 and safety of chloroquine for the treatment of COVID-19. Journal of critical care, 57, 279-283.34 Cvetkovic, R.S., Goa, K.L, 2003. Lopinavir/Ritonavir: A Review of its Use in the Management of HIV 35 Infection. Drugs, 63, 769-802. 36 de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D., Cihlar, T., Feldmann, H., 37", "latex": null, "type": "figure"}, "TABREF0": {"text": "). A Phase II and III clinical trial of 6 methylprednisolone for treatment of COVID-19 were carried out in China 7 (NCT04244591), but no results were reported yet. In a study including 66 patients 8 recovered after treatment, a remarkable lasting of viral RNA detection in oropharyngeal 9 swabs and feces from COVID-19 patients treated with corticosteroid was reported (Ling 10 Yun et al., 2020), which might be the reason why WHO does not recommend 11 glucocorticoids for COVID-19 treatment unless absolutely required. 12 IFN is a cytokine secreted by mammalian hosts during resistance to pathogens, which can 15 interfere with virus replication and enhance the antiviral ability of cells (C E, 2001). It is 16 known that IFN can be divided into three types: type I, type II, and type III (Chen Min et al., 17 2020). Type I IFN (IFN-\u03b1, IFN-\u03b2) is also called \"viral IFN\". IFN-\u03b1 inhibits both RNA and 18 DNA viruses, but does not directly kill them (C E, 2001). IFN-\u03b1 can inhibit viral gene and 19 protein synthesis by activating signaling pathways, thus activates", "latex": null, "type": "table"}, "TABREF1": {"text": "Some drugs approved for clinical therapies or under clinical trial in China 1", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Type </td><td>Mechanisms or </td><td>Primary indications </td><td>Usage against </td></tr><tr><td>Type </td><td>\u00a0</td><td>SARS-CoV-2 </td></tr><tr><td>Small-molecule drugs Lopinavir/ritonavir </td><td>Increasing the antiretroviral activity against the virus by inhibiting </td><td>HIV infection </td><td>Adviced to use in trial in </td></tr><tr><td>\u00a0</td><td>DTPNCP </td></tr><tr><td>Chloroquine phosphate </td><td>cytochrome P450. </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Preventing the replication of DNA or the transcription of </td><td>Antimalarial and </td><td>rheumatic treatment Recommended for the antiviral treatment in </td></tr><tr><td>RNA </td><td>\u00a0</td><td>DTPNCP </td></tr><tr><td>Arbidol </td><td>Inhibiting the </td><td>Influenza caused by Recommended </td></tr><tr><td>synthesis of viral </td><td>influenza A and B viruses </td><td>for the antiviral treatment in </td></tr><tr><td>\u00a0</td><td>DNA or RNA </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>DTPNCP </td></tr><tr><td>Ribavirin </td><td>Antiretroviral nucleoside drug </td><td>Sydromes of RSV, </td><td>Recommended for the antiviral treatment in </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Lassa fever or epidemic </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>21 </td></tr></table></body></html>"}}, "back_matter": []}